Synergism of a novel MCL­1 downregulator, acriflavine, with navitoclax (ABT­263) in triple­negative breast cancer, lung adenocarcinoma and glioblastoma multiforme.

Lee, Anbok; Jin, Hyeon-Ok; Masudul Haque, Md; Kim, Hee Yeon; Jung, Hana; Park, Jin Hee; Kim, Ilwhan; Song, Joo Yeon; Yoon, Hye Kyoung; Kim, Hyoung Kyu; Han, Jin; Park, In-Chul; Kim, Kwang Seok; Park, Sae Gwang

Synergism of a novel MCL1 downregulator, acriflavine, with navitoclax (ABT263) in triplenegative breast cancer, lung adenocarcinoma and glioblastoma multiforme.

Lee, Anbok; Jin, Hyeon-Ok; Masudul Haque, Md; Kim, Hee Yeon; Jung, Hana; Park, Jin Hee; Kim, Ilwhan; Song, Joo Yeon; Yoon, Hye Kyoung; Kim, Hyoung Kyu; Han, Jin; Park, In-Chul; Kim, Kwang Seok; Park, Sae Gwang.

Afiliação

Lee A; Department of Surgery, Busan Paik Hospital, College of Medicine, Inje University, Busan 47392, Republic of Korea.
Jin HO; KIRAMS Radiation Biobank, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Republic of Korea.
Masudul Haque M; Department of Microbiology and Immunology, College of Medicine, Inje University, Busan 47392, Republic of Korea.
Kim HY; Department of Surgery, Busan Paik Hospital, College of Medicine, Inje University, Busan 47392, Republic of Korea.
Jung H; Department of Microbiology and Immunology, College of Medicine, Inje University, Busan 47392, Republic of Korea.
Park JH; Department of Microbiology and Immunology, College of Medicine, Inje University, Busan 47392, Republic of Korea.
Kim I; Department of Internal Medicine, Division of Oncology, Haeundae Paik Hospital, College of Medicine, Inje University, Busan 48108, Republic of Korea.
Song JY; Department of Pathology, Dongnam Institute of Radiological and Medical Sciences, Busan 46033, Republic of Korea.
Yoon HK; Department of Pathology, Inje University, Busan 47392, Republic of Korea.
Kim HK; Cardiovascular and Metabolic Disease Center, Smart Marine Therapeutic Center, College of Medicine, Inje University, Busan 47397, Republic of Korea.
Han J; Cardiovascular and Metabolic Disease Center, Smart Marine Therapeutic Center, College of Medicine, Inje University, Busan 47397, Republic of Korea.
Park IC; Division of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Republic of Korea.
Kim KS; Division of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Republic of Korea.
Park SG; Department of Microbiology and Immunology, College of Medicine, Inje University, Busan 47392, Republic of Korea.

Int J Oncol ; 60(1)2022 01.

Article em En | MEDLINE | ID: mdl-34913076

Assuntos

Adenocarcinoma de Pulmão/tratamento farmacológico; Glioblastoma/tratamento farmacológico; Proteína de Sequência 1 de Leucemia de Células Mieloides/antagonistas & inibidores; Neoplasias de Mama Triplo Negativas/tratamento farmacológico; Acriflavina/farmacologia; Acriflavina/uso terapêutico; Compostos de Anilina/farmacologia; Compostos de Anilina/uso terapêutico; Linhagem Celular Tumoral/efeitos dos fármacos; Regulação para Baixo/efeitos dos fármacos; Combinação de Medicamentos; Humanos; Proteína de Sequência 1 de Leucemia de Células Mieloides/uso terapêutico; Sulfonamidas/farmacologia; Sulfonamidas/uso terapêutico

Palavras-chave

acriflavine; drug resistance; myeloid cell leukemia sequence 1 downregulation; navitoclax; triplenegative breast cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Glioblastoma / Neoplasias de Mama Triplo Negativas / Proteína de Sequência 1 de Leucemia de Células Mieloides / Adenocarcinoma de Pulmão Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google